The CYTO-PV: A Large-Scale Trial Testing the Intensity of CYTOreductive Therapy to Prevent Cardiovascular Events in Patients with Polycythemia Vera
Thrombosis · 2011
DOI: 10.1155/2011/794240 ↗Kurz gefasst
Fachartikel in der Zeitschrift Thrombosis, 2011. Verfasst von Roberto Marchioli und 5 weiteren Autor:innen. Beteiligte Einrichtung: CYTO-PV Coordinating Center, Consorzio Mario Negri Sud, Via Nazionale, 66030 Santa Maria Imbaro, Italy. Die Arbeit wurde bisher 58-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 3.0). Gefördert von: Italian National Drug Agency.
Abstract (Originalsprache)
Polycythemia vera (PV) is a chronic myeloproliferative disorder whose major morbidity and mortality are thrombohaemorragic events. Current guidelines advise maintaining hematocrit (HCT) level below 45% in males and 42% in females. Such targets lean on pathophysiological reasoning, while evidence from ECLAP and PVSG-01, the two largest prospective studies in this disease, suggests no difference in the rate of thrombosis in patients maintained at different HCT values below 50%–52%. Cytoreductive therapy in PV (CYTO-PV) is a multicenter, randomized, and controlled trial assess the benefit/risk profile of cytoreductive therapy with phlebotomy or HU aimed at maintaining HCT < 45% versus maintaining HCT in the range 45%–50%. CYTO-PV is being conducted in the framework of the Gruppo Italiano Malattie Ematologiche nell'Adulto (GIMEMA) and is funded by the Italian Drug Agency (AIFA). It is an independent trial with broad recruitment criteria to mimic clinical practice. We describe here the study and its advancement status. Conclusions . Clinical research in rare disease can be carried out with limited funds, provided a research hypothesis is felt as clinically relevant by a scientific community willing to share knowledge on the outcome of clinical practice, thus producing scientific results useful to improve treatment and prognosis of patients.
Autor:innen und Institutionen
- CYTO-PV Coordinating Center, Consorzio Mario Negri Sud, Via Nazionale, 66030 Santa Maria Imbaro, Italy.
Förderung
- Italian National Drug Agency
Zitieren
APA
Marchioli, R., Finazzi, G., Specchia, G., Masciulli, A., Mennitto, M. R., & Barbui, T. (2011). The CYTO-PV: A Large-Scale Trial Testing the Intensity of CYTOreductive Therapy to Prevent Cardiovascular Events in Patients with Polycythemia Vera. Thrombosis. https://doi.org/10.1155/2011/794240
Vancouver
Marchioli R, Finazzi G, Specchia G, Masciulli A, Mennitto MR, Barbui T. The CYTO-PV: A Large-Scale Trial Testing the Intensity of CYTOreductive Therapy to Prevent Cardiovascular Events in Patients with Polycythemia Vera. Thrombosis. 2011. doi:10.1155/2011/794240
BibTeX
@article{Marchioli2011,
author = {Marchioli, Roberto and Finazzi, Guido and Specchia, Giorgina and Masciulli, Arianna and Mennitto, Maria Rosaria and Barbui, Tiziano},
title = {The CYTO-PV: A Large-Scale Trial Testing the Intensity of CYTOreductive Therapy to Prevent Cardiovascular Events in Patients with Polycythemia Vera},
journal = {Thrombosis},
year = {2011},
doi = {10.1155/2011/794240}
}
EUVIMED